Novartis Heart Drug Fails Late-Stage Trial, Dragging Down Amgen and Eli Lilly Shares
Novartis said its experimental heart drug pelacarsen failed to reduce heart attacks, strokes, or deaths in a late-stage clinical trial, a setback that erased billions…
Read More
Center


